Shanghai Huaota Biopharmaceutical Co., Ltd.
上海華奧泰生物藥業股份有限公司
Licensing announcements since 2025
| Date | Counterparty | Asset / platform | Upfront | Near-term | Potential total | Stage at announcement |
|---|---|---|---|---|---|---|
| 2026-03-27 | Almirall, S.A. | Monoclonal antibody candidate | Not disclosed | Not disclosed | ≤ USD 340,000,000 | Early development; phase undisclosed |